RU95110698A - Способ лечения инфекций, вызываемых вирусом гепатита в - Google Patents
Способ лечения инфекций, вызываемых вирусом гепатита вInfo
- Publication number
- RU95110698A RU95110698A RU95110698/14A RU95110698A RU95110698A RU 95110698 A RU95110698 A RU 95110698A RU 95110698/14 A RU95110698/14 A RU 95110698/14A RU 95110698 A RU95110698 A RU 95110698A RU 95110698 A RU95110698 A RU 95110698A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- hepatitis
- virus
- infections caused
- monophosphate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Изобретение относится к способу лечения людей, инфицированных вирусом гепатита В, заключающемуся во введении эффективного количества энантиомерно чистого бета-1-диоксоланилпуриннуклеозида формулы (I), где R - ОН, С1, NНили Н, а X выбирают из группы, включающей в себя алкил, ацил, монофосфат, дифосфат и трифосфа, или его фармацевтически приемлемой соли.
Claims (1)
- Изобретение относится к способу лечения людей, инфицированных вирусом гепатита В, заключающемуся во введении эффективного количества энантиомерно чистого бета-1-диоксоланилпуриннуклеозида формулы (I), где R - ОН, С1, NН2 или Н, а X выбирают из группы, включающей в себя алкил, ацил, монофосфат, дифосфат и трифосфа, или его фармацевтически приемлемой соли.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/967,460 | 1992-10-28 | ||
US07/967,460 US5444063A (en) | 1990-12-05 | 1992-10-28 | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
Publications (2)
Publication Number | Publication Date |
---|---|
RU95110698A true RU95110698A (ru) | 1996-12-20 |
RU2157215C2 RU2157215C2 (ru) | 2000-10-10 |
Family
ID=25512829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU95110698/14A RU2157215C2 (ru) | 1992-10-28 | 1993-10-28 | Способ лечения инфекций, вызываемых вирусом гепатита в |
Country Status (15)
Country | Link |
---|---|
US (4) | US5444063A (ru) |
EP (1) | EP0666749B1 (ru) |
JP (1) | JP3117217B2 (ru) |
KR (1) | KR100304246B1 (ru) |
CN (3) | CN1044089C (ru) |
AT (1) | ATE165004T1 (ru) |
AU (1) | AU693079B2 (ru) |
CA (2) | CA2147893C (ru) |
DE (1) | DE69318031T2 (ru) |
DK (1) | DK0666749T3 (ru) |
ES (1) | ES2115918T3 (ru) |
HK (2) | HK1014663A1 (ru) |
RU (1) | RU2157215C2 (ru) |
TW (1) | TW420612B (ru) |
WO (1) | WO1994009793A1 (ru) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6350753B1 (en) | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
US6903224B2 (en) | 1988-04-11 | 2005-06-07 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes |
US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
US6069252A (en) * | 1990-02-01 | 2000-05-30 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5925643A (en) * | 1990-12-05 | 1999-07-20 | Emory University | Enantiomerically pure β-D-dioxolane-nucleosides |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
US5627160A (en) * | 1993-05-25 | 1997-05-06 | Yale University | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents |
TW374087B (en) * | 1993-05-25 | 1999-11-11 | Univ Yale | L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents |
US20020120130A1 (en) * | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
US5869461A (en) * | 1995-03-16 | 1999-02-09 | Yale University | Reducing toxicity of L-nucleosides with D-nucleosides |
ES2276404T3 (es) * | 1995-06-07 | 2007-06-16 | Emory University | Nucleosidos con actividad antivirus de la hepatitis-b. |
US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
SK48199A3 (en) * | 1996-10-16 | 2000-01-18 | Icn Pharmaceuticals | Purine l-nucleosides, analogs and uses thereof |
US6022876A (en) * | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
US20030100532A1 (en) * | 1997-02-14 | 2003-05-29 | Gary S. Jacob | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections |
MY122185A (en) * | 1998-02-12 | 2006-03-31 | Searle & Co | Use of n-substituted-1, 5-dideoxy-1, 5-imino-d-glucitol compounds for treating hepatitis virus infections |
KR100856416B1 (ko) | 1998-08-12 | 2008-09-04 | 길리애드 사이언시즈, 인코포레이티드 | 1,3-옥사티올란 뉴클레오시드의 제조 방법 |
TR200100642T2 (tr) * | 1998-08-25 | 2001-07-23 | Yale University | Helioksantin ve analogları ile hepatit B virüsü ve flavivirüsün engellenmesi ve tedavisi. |
US6979561B1 (en) | 1998-10-09 | 2005-12-27 | Gilead Sciences, Inc. | Non-homogeneous systems for the resolution of enantiomeric mixtures |
CN1666742A (zh) | 1998-11-02 | 2005-09-14 | 三角药物公司 | 对乙型肝炎病毒的联合治疗 |
US6407077B1 (en) | 1998-11-05 | 2002-06-18 | Emory University | β-L nucleosides for the treatment of HIV infection |
OA11741A (en) | 1998-12-23 | 2005-05-13 | Iaf Biochem Int | Antiviral nucleoside analogues. |
ATE402701T1 (de) * | 1999-02-12 | 2008-08-15 | United Therapeutics Corp | N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen |
US6511983B1 (en) | 1999-03-01 | 2003-01-28 | Biochem Pharma Inc. | Pharmaceutical combination of antiviral agents |
US6514979B1 (en) * | 1999-03-03 | 2003-02-04 | University Of Maryland Biotechnology Institute | Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor |
US6653318B1 (en) | 1999-07-21 | 2003-11-25 | Yale University | 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use |
CA2389745C (en) | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
US6436948B1 (en) | 2000-03-03 | 2002-08-20 | University Of Georgia Research Foundation Inc. | Method for the treatment of psoriasis and genital warts |
KR101015510B1 (ko) * | 2001-03-01 | 2011-02-16 | 길리애드 사이언시즈, 인코포레이티드 | 시스-ftc의 다형 및 기타 결정형 |
AU2003261114A1 (en) * | 2002-07-03 | 2004-02-09 | Triangle Pharmaceuticals, Inc. | Combination therapy with 1,3-dioxolanes and inosine monophosphate dehydrogenase inhibitors |
DE10335061B4 (de) * | 2003-07-31 | 2005-11-17 | Wacker-Chemie Gmbh | Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten |
US7785839B2 (en) | 2004-02-03 | 2010-08-31 | Emory University | Methods to manufacture 1,3-dioxolane nucleosides |
WO2005107742A1 (en) | 2004-05-05 | 2005-11-17 | Yale University | Novel antiviral helioxanthin analogs |
NO324263B1 (no) | 2005-12-08 | 2007-09-17 | Clavis Pharma Asa | Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
CA2656959A1 (en) | 2006-07-07 | 2008-01-10 | Meiji Seika Kaisha, Ltd. | Prophylactic or therapeutic agent for viral disease |
WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
BRPI0808089A2 (pt) | 2007-02-28 | 2014-07-15 | Conatus Pharmaceuticals Inc | Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c. |
WO2010091386A2 (en) | 2009-02-06 | 2010-08-12 | Rfs Pharma, Llc | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections |
US20120142627A1 (en) * | 2010-12-06 | 2012-06-07 | Emory University | Monophosphate prodrugs of dapd and analogs thereof |
NZ729118A (en) * | 2014-08-25 | 2022-02-25 | Medivir Ab | Dioxolane analogues of uridine for the treatment of cancer |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3116282A (en) * | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
US4000137A (en) * | 1975-06-10 | 1976-12-28 | American Home Products Corporation | Antitumor derivatives of periodate-oxidized nucleosides |
US4140761A (en) * | 1977-04-11 | 1979-02-20 | The United States Of America As Represented By The Department Of Health, Education & Welfare | Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen |
JPS5668674A (en) * | 1979-11-08 | 1981-06-09 | Shionogi & Co Ltd | 5-fluorouracil derivative |
NZ216172A (en) * | 1985-05-15 | 1989-08-29 | Wellcome Found | Nucleosides and pharmaceutical compositions |
US4879277A (en) * | 1985-08-26 | 1989-11-07 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral compositions and methods |
JPS62501712A (ja) * | 1985-08-26 | 1987-07-09 | アメリカ合衆国 | 2′、3′―ジデオキシイノシン、2′,3′―ジデオキシグアノシンまたは2′,3′―ジデオキシアデノシンを含有する抗htlv―3/lav剤 |
GB2181128A (en) * | 1985-09-17 | 1987-04-15 | Wellcome Found | 3'-azidonucleosides |
IN164556B (ru) * | 1986-03-06 | 1989-04-08 | Takeda Chemical Industries Ltd | |
US4916122A (en) * | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
US5446029A (en) * | 1986-07-04 | 1995-08-29 | Medivir Ab | Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides |
US4963533A (en) * | 1986-10-24 | 1990-10-16 | Stichting Rega Vzw (Rega) | Therapeutic application of dideoxycytidinene |
US5215971A (en) * | 1986-12-19 | 1993-06-01 | Medivir Ab | Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides |
US5185437A (en) * | 1987-04-09 | 1993-02-09 | Burroughs Wellcome Co. | Therapeutic nucleosides |
US5215970A (en) * | 1987-04-16 | 1993-06-01 | Medivir Ab | Nucleosides and nucleotide analogues, pharmaceutical composition and processes for the preparation of the compounds |
LU86927A1 (de) * | 1987-06-19 | 1988-07-14 | Europ Communities | Kontinuierlich variables laserstrahl-daempfungsglied |
US5011774A (en) * | 1987-07-17 | 1991-04-30 | Bristol-Myers Squibb Co. | Dideoxyinosine by enzymatic deamination of dideoxyadenosine |
US5246924A (en) * | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
US4880784A (en) * | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5041449A (en) * | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
US5270315A (en) * | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
NZ228645A (en) * | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
US5122517A (en) * | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
GB8822546D0 (en) * | 1988-09-26 | 1988-11-02 | Wellcome Found | Antiviral combinations |
EP0375329B1 (en) * | 1988-12-19 | 1995-05-31 | The Wellcome Foundation Limited | Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them |
AU3154993A (en) * | 1989-02-08 | 1994-07-19 | Biochem Pharma Inc. | Process for preparing substituted 1,3-oxathiolanes with antiviral properties |
UA45942A (uk) * | 1989-02-08 | 2002-05-15 | Біокем Фарма, Інк. | 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція |
NZ233197A (en) * | 1989-04-13 | 1991-11-26 | Richard Thomas Walker | Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions |
US5059690A (en) * | 1990-03-01 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Purinyl tetrahydrofurans |
IE904378A1 (en) * | 1989-12-20 | 1991-07-03 | Abbott Lab | Analogs of oxetanyl purines and pyrimidines |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
DE69128275T2 (de) * | 1990-07-18 | 1998-03-19 | Nippon Hypox Lab Inc | Aus einem süssholzextrakt hergestellte zusammenstellung für ein funktionelles nahrungsmittel und medikament |
SE9003151D0 (sv) * | 1990-10-02 | 1990-10-02 | Medivir Ab | Nucleoside derivatives |
WO1992008717A1 (en) * | 1990-11-13 | 1992-05-29 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
US5925643A (en) * | 1990-12-05 | 1999-07-20 | Emory University | Enantiomerically pure β-D-dioxolane-nucleosides |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
US5248776A (en) * | 1990-12-05 | 1993-09-28 | University Of Georgia Research Foundation, Inc. | Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides |
US5179104A (en) * | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
WO1992010496A1 (en) * | 1990-12-05 | 1992-06-25 | University Of Georgia Research Foundation, Inc. | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES |
IL100502A (en) * | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
IL100965A (en) * | 1991-02-22 | 1999-12-31 | Univ Emory | 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it |
GB9104740D0 (en) * | 1991-03-06 | 1991-04-17 | Wellcome Found | Antiviral nucleoside combination |
KR100270806B1 (ko) * | 1991-03-06 | 2000-11-01 | 템블 존 엘 | 5-플루오로-2`-데옥시-3`-티아시티딘을 함유하는 b형 간염 치료를 위한 약제 |
WO1992018517A1 (en) * | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
GB9110874D0 (en) * | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
ZA923640B (en) * | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
GB9111902D0 (en) * | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
US5432165A (en) * | 1992-04-06 | 1995-07-11 | Oclassen Pharmaceuticals, Inc. | Methods for the treatment of infection caused by Hepatitis B virus (HBV) |
GB9226927D0 (en) * | 1992-12-24 | 1993-02-17 | Iaf Biochem Int | Dideoxy nucleoside analogues |
US5627160A (en) * | 1993-05-25 | 1997-05-06 | Yale University | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents |
FR2709754B1 (fr) * | 1993-09-10 | 1995-12-01 | Centre Nat Rech Scient | Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale. |
CA2171550C (en) * | 1993-09-10 | 2008-08-26 | Raymond F. Schinazi | Nucleosides with anti-hepatitis b virus activity |
US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
-
1992
- 1992-10-28 US US07/967,460 patent/US5444063A/en not_active Expired - Lifetime
-
1993
- 1993-10-16 TW TW082108587A patent/TW420612B/zh not_active IP Right Cessation
- 1993-10-28 CN CN93120708A patent/CN1044089C/zh not_active Expired - Fee Related
- 1993-10-28 AT AT94900424T patent/ATE165004T1/de active
- 1993-10-28 WO PCT/US1993/010348 patent/WO1994009793A1/en active IP Right Grant
- 1993-10-28 ES ES94900424T patent/ES2115918T3/es not_active Expired - Lifetime
- 1993-10-28 JP JP06511314A patent/JP3117217B2/ja not_active Expired - Fee Related
- 1993-10-28 CA CA002147893A patent/CA2147893C/en not_active Expired - Fee Related
- 1993-10-28 KR KR1019950701648A patent/KR100304246B1/ko not_active IP Right Cessation
- 1993-10-28 CA CA002268703A patent/CA2268703C/en not_active Expired - Fee Related
- 1993-10-28 DE DE69318031T patent/DE69318031T2/de not_active Expired - Lifetime
- 1993-10-28 CN CNB961134259A patent/CN1195526C/zh not_active Expired - Fee Related
- 1993-10-28 RU RU95110698/14A patent/RU2157215C2/ru not_active IP Right Cessation
- 1993-10-28 AU AU55419/94A patent/AU693079B2/en not_active Ceased
- 1993-10-28 CN CNB2005100080312A patent/CN100345552C/zh not_active Expired - Fee Related
- 1993-10-28 EP EP94900424A patent/EP0666749B1/en not_active Expired - Lifetime
- 1993-10-28 DK DK94900424T patent/DK0666749T3/da active
-
1995
- 1995-06-06 US US08/471,533 patent/US5684010A/en not_active Expired - Lifetime
-
1997
- 1997-04-15 US US08/839,713 patent/US5834474A/en not_active Expired - Lifetime
- 1997-04-15 US US08/838,072 patent/US5830898A/en not_active Expired - Lifetime
-
1998
- 1998-12-28 HK HK98116017A patent/HK1014663A1/xx not_active IP Right Cessation
-
2006
- 2006-04-11 HK HK06104417A patent/HK1082684A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2115918T3 (es) | 1998-07-01 |
AU5541994A (en) | 1994-05-24 |
CA2268703A1 (en) | 1994-05-11 |
ATE165004T1 (de) | 1998-05-15 |
KR100304246B1 (ko) | 2003-12-31 |
CA2147893A1 (en) | 1994-05-11 |
CN1679612A (zh) | 2005-10-12 |
DK0666749T3 (da) | 1999-01-04 |
CN1044089C (zh) | 1999-07-14 |
US5830898A (en) | 1998-11-03 |
CA2268703C (en) | 2001-05-01 |
CN100345552C (zh) | 2007-10-31 |
CN1152435A (zh) | 1997-06-25 |
HK1082684A1 (en) | 2006-06-16 |
WO1994009793A1 (en) | 1994-05-11 |
HK1014663A1 (en) | 1999-09-30 |
CA2147893C (en) | 1999-06-22 |
US5684010A (en) | 1997-11-04 |
DE69318031T2 (de) | 1998-09-03 |
US5444063A (en) | 1995-08-22 |
RU2157215C2 (ru) | 2000-10-10 |
DE69318031D1 (de) | 1998-05-20 |
CN1195526C (zh) | 2005-04-06 |
JP3117217B2 (ja) | 2000-12-11 |
EP0666749B1 (en) | 1998-04-15 |
CN1092427A (zh) | 1994-09-21 |
TW420612B (en) | 2001-02-01 |
AU693079B2 (en) | 1998-06-25 |
EP0666749A1 (en) | 1995-08-16 |
JPH08507286A (ja) | 1996-08-06 |
US5834474A (en) | 1998-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU95110698A (ru) | Способ лечения инфекций, вызываемых вирусом гепатита в | |
CA2197319A1 (en) | Lipid analogs for treating viral infections | |
ES541103A0 (es) | Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales | |
RU95108243A (ru) | Производные амидов вальпроновой и 2-вальпроеновой кислоты, фармацевтическая композиция, способы лечения | |
DE69431596D1 (de) | (phospho)lipide zum bekämpfen einer hepatitis b-infektion | |
KR900015742A (ko) | 항 비루스 제 | |
ES2157929T3 (es) | Beta-d-dioxolano-nucleosidos enantiomeramente puros. | |
ATE188871T1 (de) | Verfahren zur behandlung von viralen infectionen | |
DE69929460D1 (de) | Nukleoside mit anti-hepatitis b virus wirkung | |
DK0476066T3 (da) | Antiviralt præparat indeholdende 3-azido-2,3-dideoxy-5-methylcytidin | |
ES2105923A1 (es) | Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). | |
KR950701638A (ko) | 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues) | |
KR910018393A (ko) | 항바이러스제로서의 비대칭 2-(포스포노메톡시)프로필 구아닌 | |
MY104521A (en) | Treatment of depression. | |
DE69019404T2 (de) | Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen. | |
KR910018341A (ko) | 신규 α-만노시다제 및 푸코시다제 억제제 | |
UA42693C2 (ru) | Лекарственное средство для лечения инфекции лентивирусом, препарат для лечения человека, который инфицирован лентивирусом | |
RU2001115094A (ru) | Нуклеозиды, обладающие активностью против вируса гепатита в | |
DE69930678D1 (de) | Azidoderivate von beta-l-2'-nukleosiden zur hiv-infektionsbehandlung | |
FR2455598A1 (fr) | Nouveaux derives 5- (2- ((2,3-dihydro-1,4-benzodioxanne-2-ylmethyl)- amino)-1- hydroxyethyl)-2-hydroxybenzoiques, utiles notamment comme agents bloquants des recepteurs adrenergiques a et b, et leur procede de preparation | |
RU97111796A (ru) | Использование аминопуриновых противовирусных соединений для лечения и профилактики латентных инфекций, вызванных вирусом герпеса | |
DE69311135D1 (de) | Zubereitungen, die acyclovir-ähnliche verbindungen und 2'-vinylsubstituierte nukleosidanaloge enthalten, zur behandlung viraler infektionen | |
RU2001134133A (ru) | Использование аминопуриновых противовирусных соединений для лечения и профилактики латентных инфекций, вызванных вирусом герпеса | |
MY101495A (en) | Treatment of diseases caused by viruses | |
RU94002713A (ru) | Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20111029 |